Say no to DMSO: Dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes

Cancer Research

Volumn 74, Issue 14, 2014, Pages 3913-3922

  Hall, Matthew D ^a   Telma, Katherine A ^a   Chang, Ki Eun ^a   Lee, Tobie D ^a   Madigan, James P ^a   Lloyd, John R ^b   Goldlust, Ian S ^c   Hoeschele, James D ^d   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d EASTERN MICHIGAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CARBOPLATIN; CASPASE 3; CISPLATIN; DIMETHYL SULFOXIDE; HISTONE H2AX; OXALIPLATIN; SATRAPLATIN; TRANSPLATIN; WATER;

ARTICLE; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CHEMICAL INTERACTION; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG INACTIVATION; DRUG INFORMATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; SOLVATION;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; DIMETHYL SULFOXIDE; HUMANS; INHIBITORY CONCENTRATION 50; PLATINUM COMPOUNDS; SOLVENTS;

EID: 84904247086     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0247     Document Type: Article

References (50)

1. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-90.
2. Eastman A. The Mechanism of Action of Cisplatin: From Adducts to Apoptosis. In:Lippert B, editor. Cisplatin: chemistry and biochemistry of a leading anticancer drug. Zurich, Switzerland: Verlag Helvetica Chimica Acta; 1999. p. 111-34.
3. Gottesman MM, Hall MD, Liang XJ, Shen DW. Resistance to Cisplatin Results from Multiple Mechanisms in Cancer Cells. In:Bonetti A, Muggia FM, Leone R, Howell SB, editors. Platinum and other heavy metal compounds in cancer chemotherapy. New York: Humana Press; 2009. p. 83-8.
4. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM. The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy. Annu Rev Pharmacol Toxicol 2008;48:495-535. (Pubitemid 351738162)
5. Hall MD, Handley MD, Gottesman MM. Is resistance useless? Multi-drug resistance and collateral sensitivity. Trends Pharmacol Sci 2009;30:546-56.
6. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes. Pharmacol Rev 2012;64:706-21.
7. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20. (Pubitemid 41130944)
8. Hambley TW. The influence of structure on the activity and toxicity of Pt anti-cancer drugs. Coord Chem Rev 1997;166:181-223. (Pubitemid 127452076)
9. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84. (Pubitemid 47106628)
10. Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum (II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986;46:1972-9. (Pubitemid 16080411)
11. Martin RB. Platinum Complexes: Hydrolysis and Binding to N(7) and N (1) of Purines. In:Lippert B, editor. Cisplatin: chemistry and biochemistry of a leading anticancer drug. Weinheim: Wiley-VCH; 1999. p. 183-205.
12. Pereira DA, Williams JA. Origin and evolution of high throughput screening. Br J Pharmacol 2007;152:53-61. (Pubitemid 47339909)
13. Kerrison SJS, Sadler PJ. Solvolysis of cis-[Pt(NH3)2Cl2] in dimethyl sulphoxide and reactions of glycine with [PtCl3(Me2SO)]- as probed by 195Pt nuclear magnetic resonance shifts and 195Pt-15N coupling constants. Chem Commun 1977:861-3.
14. Kerrison SJS, Sadler PJ. 195Pt NMR studies of platinum(II) dimethylsuphoxide complexes. Inorganica Chimica Acta 1985;104:197-201.
15. Farrell N, Kiley DM, Schmidt W, Hacker MP. Chemical properties and antitumor activity of complexes of platinum containing substituted sulfoxides [PtCl(R′R″SO)(diamine)]NO3. Chirality and leaving-group ability of sulfoxide affecting biological activity. Inorg Chem 1990;29:397-403.
16. Annibale G, Cattalani L, Canovese L, Michelon G, Marangoni G, Tobe ML. Reactivity of sulfoxides toward the tetrachloroplatinate(II) anion. Inorg Chem 1983;22:975-8.
17. Massart C, Le Tellier C, Gibassier J, Leclech G, Nicol M. Modulation by dimethyl sulphoxide of the toxicity induced by cis-diamminedichloroplatinum in cultured thyrocytes. Toxicol In Vitro 1993;7: 87-94.
18. Dernell WS, Straw RC, Withrow SJ, Powers BE, Fujita SM, Yewey GS, et al. Apparent interaction of dimethyl sulfoxide with cisplatin released from polymer delivery devices injected subcutaneously in dogs. J Drug Target 1998;5:391-6. (Pubitemid 28451326)
19. Peaston A, Maddison J. Treatment of superficial tumours on horses with dimethyl sulfoxide and cisplatin. Aust Vet J 1995;72:76-7.
20. Liang XJ, Shen DW, Garfield S, Gottesman MM. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res 2003;63:5909-16. (Pubitemid 37187492)
21. Shen D, Pastan I, Gottesman MM. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 1998;58: 268-75. (Pubitemid 28047066)
22. Pei XY, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, et al. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood 2011;118:5189-200.
23. Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A 2011;108: 1433-8.
24. Alderden RA, Hall MD, Hambley TW. The discovery and development of cisplatin. J Chem Ed 2006;83:728-34.
25. Davies MS, Berners-Price SJ, Hambley TW. Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA. Inorganic Chem 2000;39:5603-13. (Pubitemid 32065704)
26. Jennerwein M, Andrews PA. Drug accumulation andDNA platination in cells exposed to aquated cisplatin species. Cancer Lett 1994;81: 215-20. (Pubitemid 24184658)
27. Shirazi HH, Molepo JM, Stewart DJ, Ng CE, Raaphorst GP, Goel R. Cytotoxicity, accumulation, and efflux of cisplatin and its metabolites in human ovarian carcinoma cells. Toxicol Appl Pharmacol 1996; 140:211-8. (Pubitemid 26366843)
28. Giandomenico CM, Abrams MJ, Murrer BA, Vollano JF, Rheinheimer MI, Wyer SB, et al. Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entry into orally active platinum(IV) antitumor agents. Inorg Chem 1995;34:1015-21.
29. Choy H. Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Rev Anticancer Ther 2006;6:973-82. (Pubitemid 44203377)
30. Rosenberg B, Charles F. Kettring prize. Fundamental studies with cisplatin. Cancer 1985;55:2303-16. (Pubitemid 15115175)
31. Schnurr B, Heinrich H, Gust R. Investigations on the decomposition of carboplatin in infusion solutions II. Effect of 1,1-cyclobutanedicarboxylic acid admixture. Microchimica Acta 2002;140:141-8.
32. Di Pasqua AJ, Kerwood DJ, Shi Y, Goodisman J, Dabrowiak JC. Stability of carboplatin and oxaliplatin in their infusion solutions is due to self-association. Dalton Trans 2011;40:4821-5.
33. Aris SM, Farrell NP. Towards antitumor active trans-platinum compounds. Eur J Inorg Chem 2009;2009:1293.
34. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 2000;275:9390-5. (Pubitemid 30185164)
35. Chiu SJ, Lee YJ, Hsu TS, Chen WS. Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells. Chem Biol Interact 2009;182:173-82.
36. Cruet-Hennequart S, Villalan S, Kaczmarczyk A, O'Meara E, SokolAM, Carty MP. Characterization of the effects of cisplatin and carboplatin on cell cycle progression andDNAdamage response activation inDNA polymerase eta-deficient human cells. Cell Cycle 2009;8:3039-50.
37. Wu YJ, Muldoon LL, Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 2005;312:424-31. (Pubitemid 40189538)
38. Fischer SJ, Benson LM, Fauq A, Naylor S, Windebank AJ. Cisplatin and dimethyl sulfoxide react to form an adducted compound with reduced cytotoxicity and neurotoxicity. Neurotoxicology 2008;29:444-52.
39. Melanson R, Rochon FD. cis-Dichloro(ammine)(dimethyl sulphoxide) platinum(II). Acta Cryst 1978;B34:941-3.
40. Hall M, Mellor H, Callaghan R, Hambley T. Basis for design and development of Platinum(IV) anticancer complexes. J Med Chem 2007;50:3403-11. (Pubitemid 47195446)
41. Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, et al. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov 2010;9:843-56.
42. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8. (Pubitemid 32778603)
43. Ioannidis JP. Why most published research findings are false. PLoS MED 2005;2:e124.
44. Margiotta N, Denora N, Ostuni R, Laquintana V, Anderson A, Johnson SW, et al. Platinum(II) complexes with bioactive carrier ligands having high affinity for the translocator protein. J Med Chem 2010;53:5144-54.
45. Yi YW, Bae I. Effects of solvents on in vitro potencies of platinum compounds. DNA Repair 2011;10:1084-5.
46. Gescher A. Metabolism of N,N-dimethylformamide: key to the understanding of its toxicity. Chem Res Toxicol 1993;6:245-51. (Pubitemid 23146584)
47. Jones MM, Basinger MA, Field L, Holscher MA. Coadministration of dimethyl sulfoxide reduces cisplatin nephrotoxicity. Anticancer Res 1991;11:1939-42.
48. Reedijk J. Why does Cisplatin reach Guanine-n7 with competing s-donor ligands available in the cell? Chem Rev 1999;99:2499-510.
49. Tanley SW, Schreurs AM, Kroon-Batenburg LM, Meredith J, Prendergast R, Walsh D, et al. Structural studies of the effect that dimethyl sulfoxide (DMSO) has on cisplatin and carboplatin binding to histidine in a protein. Acta Crystallogr D Biol Crystallogr 2012; 68:601-12.
50. Uribe PM, Mueller MA, Gleichman JS, Kramer MD, Wang Q, Sibrian-Vazquez M, et al. Dimethyl sulfoxide (DMSO) exacerbates cisplatin-induced sensory hair cell death in zebrafish (Danio rerio). PLoS ONE 2013;8:e55359.